Across TCGA pan-cancer cohorts, RFLNB mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RFLNB data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RFLNB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RFLNB expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where RFLNB mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.199	0.621	.010	27	view →
CCRCC	DFS	Tertile	III,IV	0.797	0.335	.001	17	view →
HNSC	DFS	Tertile	IV	0.584	0.906	.012	10	view →
GBM	OS	Median	All	0.556	0.268	.018	6	view →
LUAD	DFS	Tertile	III,IV	0.546	0.995	.031	5	view →
LSCC	OS	Tertile	All	0.962	1.000	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: RFLNB tumor-vs-normal RNA expression · all RFLNB data types